Unknown NA INTERVENTIONAL 3-arm NCT00922688

Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients (AIRCo)

Sponsor: Medical Center Alkmaar

Interventions Dipeptide Alanyl-Glutamine Placebo

Updated 5 times since 2017 Last updated: Jul 20, 2011 Started: Dec 31, 2010 Primary completion: Dec 31, 2012 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00922688, this NA trial focuses on Colon Carcinoma and remains ongoing. Sponsored by Medical Center Alkmaar, it has been updated 5 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical Center Alkmaar

Data source: Medical Center Alkmaar

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Alkmaar, Netherlands